2024 UBS Global Healthcare Conference on
November 12
Stifel 2024 Healthcare Conference on
November 18
Jefferies London Healthcare Conference on
November 19
SAN
DIEGO, Nov. 5, 2024 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming
investor conferences in November.
- Chief Executive Officer Kyle
Gano, Chief Financial Officer Matt
Abernethy, and Vice-President of Investor Relations
Todd Tushla will present at the 2024
UBS Global Healthcare Conference at 1:15
p.m. Pacific Time (4:15 p.m. Eastern
Time) on Tuesday November 12,
2024 in Rancho Palos Verdes,
CA.
- Chief Financial Officer Matt
Abernethy and Chief Commercial Officer Eric Benevich will present at the Stifel 2024
Healthcare Conference at 10:55 a.m. Eastern
Time on Monday November 18, 2024 in New York.
- Chief Executive Officer Kyle
Gano, Chief Financial Officer Matt
Abernethy, and Chief Medical Officer Eiry Roberts will
present at the Jefferies London Healthcare Conference at
1:30 p.m. Greenwich Mean Time
(8:30 a.m. Eastern Time) on
Tuesday November 19, 2024 in
London, United Kingdom.
The live presentations will be webcast and may be accessed on
Neurocrine Biosciences' website under Investors at
www.neurocrine.com. A replay of the webcasts will be available on
the website approximately one hour after the conclusion of the
events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a leading neuroscience-focused, biopharmaceutical company with a
simple purpose: to relieve suffering for people with great needs,
but few options. We are dedicated to discovering and developing
life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders. The
company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia, chorea associated with Huntington's disease,
endometriosis* and uterine fibroids*, as well as a robust pipeline
including multiple compounds in mid- to late-phase clinical
development across our core therapeutic areas. For three decades,
we have applied our unique insight into neuroscience and the
interconnections between brain and body systems to treat complex
conditions. We relentlessly pursue medicines to ease the burden of
debilitating diseases and disorders, because you deserve brave
science. For more information, visit neurocrine.com, and
follow the company on LinkedIn, X (Formerly Twitter) and Facebook.
(*in collaboration with AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE
SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
The Neurocrine logo is a trademark of Neurocrine Biosciences,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-november-302296896.html
SOURCE Neurocrine Biosciences, Inc.
